Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single Circulating Tumor Cells

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Dago, Angel E ^a   Stepansky, Asya ^b,c   Carlsson, Anders ^a   Luttgen, Madelyn ^a   Kendall, Jude ^b,c   Baslan, Timour ^b,d   Kolatkar, Anand ^a   Wigler, Michael ^b   Bethel, Kelly ^a,e   Gross, Mitchell E ^f   Hicks, James ^b   Kuhn, Peter ^g  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^c Skyline Genomics   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e SCRIPPS CLINIC   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN;

AR GENE; ARTICLE; CANCER RECURRENCE; CASE REPORT; CELL LINEAGE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIPLOIDY; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; MALE; MORPHOMETRICS; ONCOGENE MYC; PHENOTYPE; PHYLOGENY; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT RESPONSE; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME ABERRATION; CLONAL EVOLUTION; COPY NUMBER VARIATION; GENETICS; GENOMICS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; SINGLE CELL ANALYSIS; TUMOR EMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CLONAL EVOLUTION; DNA COPY NUMBER VARIATIONS; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; MALE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; SINGLE-CELL ANALYSIS;

EID: 84905502594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101777     Document Type: Article

References (35)

1. Ryan CJ, Tindall DJ (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29: 3651-3658.
2. Attard G, Richards J, de Bono JS (2011) New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 17: 1649-1657.
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85.
4. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209-9216. (Pubitemid 39665537)
5. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8: 329-340. (Pubitemid 351596394)
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791. (Pubitemid 39095313)
7. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221.
8. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al.(2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309.
9. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, et al. (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and nextgeneration sequencing. Cancer Res 73: 2965-2975.
10. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, et al. (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9: 016003.
11. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, et al. (2012) Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol 9: 016002.
12. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
13. Baslan T, Kendall J, Rodgers L, Cox H, Riggs M, et al. (2012) Genome-wide copy number analysis of single cells. Nat Protoc 7: 1024-1041.
14. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, et al. (2013) An Observational Study of Circulating Tumor Cells and (18)F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. PLoS One 8: e67733.
15. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, et al. (2013) The UCSC Genome Browser database: extensions and updates. Nucleic Acids Res 41: D64-69.
16. Team RC (2012) R: A Language and Environment for Statistical Computing.
17. Halir R, Flusser J (1998) Numerically stable direct least squares fitting of ellipses. Proceeding of International Conference in Central Europe on Computer Graphics, Visualization and Interactive Digital Media: 125-132.
18. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
19. Goatly A, Bacon CM, Nakamura S, Ye H, Kim I, et al. (2008) FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol 21: 902-911. (Pubitemid 351896666)
20. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122. (Pubitemid 40966196)
21. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319. (Pubitemid 27036612)
22. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, et al. (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2: 995-1003.
23. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, et al. (2010) MYC and Prostate Cancer. Genes Cancer 1: 617-628.
24. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913-5925.
25. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287: 19736-19749.
26. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, et al. (2012) Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 12: 78.
27. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, et al. (2013) Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5: 30.
28. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. (2010) Inferring tumor progression from genomic heterogeneity. Genome Res 20: 68-80.
29. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
30. Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, et al. (2014) Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74: 1338-1348.
31. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
32. Shi H, Hugo W, Kong X, Hong A, Koya RC, et al. (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4: 80-93.
33. Li B, Simon MC (2013) Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer. Clin Cancer Res.
34. Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, et al. (2013) A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. Sci Transl Med 5: 187ra171.
35. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. (2013) Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108-112.